Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhea N Coler

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Frontiers in Microbiology|February 11, 2025
Recombinase-based amplification coupled with lateral flow chromatography for the specific and sensitive detection and identification of <i>Leishmania major</i> in cutaneous leishmaniasis patientsInsaf Bel Hadj Ali, Yusr Saadi-Ben Aoun, Imen Khammeri, et al.
The Lancet. Respiratory Medicine|March 30, 2018
Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trialAdam Penn-Nicholson, Michele Tameris, Erica Smit, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|November 10, 2020
Diagnostics and the neglected tropical diseases roadmap: setting the agenda for 2030Ashley A Souza, Camilla Ducker, Daniel Argaw, et al.
Molecular Therapy. Methods & Clinical Development|July 23, 2020
Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus InfectionJesse H Erasmus, Jacob Archer, Jasmine Fuerte-Stone, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Npj Antimicrobials and Resistance|January 22, 2025
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniquesHazem F M Abdelaal, Bryan J Berube, Brendan K Podell, et al.
Clinical & Translational Immunology|July 16, 2015
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.
Infectious Diseases and Therapy|May 11, 2023
Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialYu Hwa Choi, Young Ae Kang, Kwang Joo Park, et al.
Scientific Reports|April 22, 2017
A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza VaccinesNeal Van Hoeven, Christopher B Fox, Brian Granger, et al.
NPJ Vaccines|December 22, 2017
A defined subunit vaccine that protects against vector-borne visceral leishmaniasisMalcolm S Duthie, Lais Pereira, Michelle Favila, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Frontiers in Microbiology|February 11, 2025
Recombinase-based amplification coupled with lateral flow chromatography for the specific and sensitive detection and identification of <i>Leishmania major</i> in cutaneous leishmaniasis patientsInsaf Bel Hadj Ali, Yusr Saadi-Ben Aoun, Imen Khammeri, et al.
The Lancet. Respiratory Medicine|March 30, 2018
Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trialAdam Penn-Nicholson, Michele Tameris, Erica Smit, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|November 10, 2020
Diagnostics and the neglected tropical diseases roadmap: setting the agenda for 2030Ashley A Souza, Camilla Ducker, Daniel Argaw, et al.
Molecular Therapy. Methods & Clinical Development|July 23, 2020
Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus InfectionJesse H Erasmus, Jacob Archer, Jasmine Fuerte-Stone, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Npj Antimicrobials and Resistance|January 22, 2025
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniquesHazem F M Abdelaal, Bryan J Berube, Brendan K Podell, et al.
Clinical & Translational Immunology|July 16, 2015
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.
Infectious Diseases and Therapy|May 11, 2023
Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialYu Hwa Choi, Young Ae Kang, Kwang Joo Park, et al.
Scientific Reports|April 22, 2017
A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza VaccinesNeal Van Hoeven, Christopher B Fox, Brian Granger, et al.
NPJ Vaccines|December 22, 2017
A defined subunit vaccine that protects against vector-borne visceral leishmaniasisMalcolm S Duthie, Lais Pereira, Michelle Favila, et al.
Pageof 14